Luigi Alfano, PhD, BS - NCI Pascale Foundation

Luigi Alfano

PhD, BS

NCI Pascale Foundation

Naples, Campania | Italy

Main Specialties: Biology, Molecular Genetic Pathology, Oncology

ORCID logohttps://orcid.org/0000-0002-4516-9956


Top Author

Luigi Alfano, PhD, BS - NCI Pascale Foundation

Luigi Alfano

PhD, BS

Introduction

I'm a molecular biologist at the National Cancer Institute Pascale Foundation in Naples, Italy. Actually, I'm working in the DNA repair contest in particular I'm studying the DNA damage response in order to identify a novel players as a possible druggable proteins for cancer therapy.

Primary Affiliation: NCI Pascale Foundation - Naples, Campania , Italy

Specialties:

Research Interests:


View Luigi Alfano’s Resume / CV

Education

Oct 2019
University of Naples “Federico II”
Bachelor’s Degree Viticulture and Enology Science
Feb 2010
University of Naples “Federico II” School of Medicine
Ph.D. in Molecular Oncology and Endocrinology
Feb 2010
University of Naples “Federico II” School of Medicine
Ph.D. in Molecular Oncology and Endocrinology
Sep 2006
University of Naples “Federico II” School of Medicine
Master’s Degree in Medical Biotechnologies
Sep 2006
University of Naples “Federico II” School of Medicine
Master’s Degree in Medical Biotechnologies
Sep 2006
University of Naples “Federico II” School of Medicine
Master’s Degree in Medical Biotechnologies
Feb 2005
University of Naples “Federico II” School of Medicine
Bachelor’s Degree in Medical Biotechnologies
Feb 2005
University of Naples “Federico II” School of Medicine
Bachelor’s Degree in Medical Biotechnologies
Feb 2005
University of Naples “Federico II” School of Medicine
Bachelor’s Degree in Medical Biotechnologies
Feb 2005
University of Naples “Federico II” School of Medicine
Bachelor’s Degree in Medical Biotechnologies

Experience

Feb 2019
“Le Eccellenze nelle Imprese e nelle Professioni
Awards

Publications

10Publications

240Reads

46Profile Views

RBL2/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines.

Oncogene 2018 07 2;37(27):3657-3671. Epub 2018 Apr 2.

Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Scienceand Technology, Temple University, Philadelphia, PA, 19122, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41388-018-0214-3
Publisher Site
http://dx.doi.org/10.1038/s41388-018-0214-3DOI Listing
July 2018
14 Reads
8.459 Impact Factor

NONO ubiquitination is mediated by FBW7 and GSK3 β via a degron lost upon chromosomal rearrangement in cancer.

J Cell Physiol 2018 05 29;233(5):4338-4344. Epub 2017 Dec 29.

Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Napoli, Italia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.26269DOI Listing
May 2018
130 Reads
3.839 Impact Factor

CDK9 inhibitors in acute myeloid leukemia.

J Exp Clin Cancer Res 2018 Feb 23;37(1):36. Epub 2018 Feb 23.

Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Temple University, 1900 N. 12th St., Room 431, Philadelphia, PA, 19122-6017, USA.

View Article

Download full-text PDF

Source
https://jeccr.biomedcentral.com/articles/10.1186/s13046-018-
Publisher Site
http://dx.doi.org/10.1186/s13046-018-0704-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824552PMC
February 2018
39 Reads

HUR protects NONO from degradation by mir320, which is induced by p53 upon UV irradiation.

Oncotarget 2016 Nov;7(47):78127-78139

Oncology Research Center of Mercogliano (CROM), Istituto Nazionale Per Lo Studio E La Cura Dei Tumori "Fondazione Giovanni Pascale", IRCCS, Naples, 80131, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.13002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363649PMC
November 2016
15 Reads
6.359 Impact Factor

Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.

Cancer Biol Ther 2014 Apr 14;15(4):380-8. Epub 2014 Jan 14.

Department of Medicine, Surgery and Neuroscience; University of Siena and Istituto Toscano Tumori (ITT); Siena, Italy; Sbarro Institute for Cancer Research and Molecular Medicine; Center for Biotechnology; College of Science and Technology; Temple University; Philadelphia, PA USA; Oncology Research Center of Mercogliano (CROM); Istituto Nazionale Tumori "Fondazione Giovanni Pascale"; IRCCS; Naples, Italy.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/cbt.27623
Publisher Site
http://dx.doi.org/10.4161/cbt.27623DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979815PMC
April 2014
12 Reads
3.072 Impact Factor

Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.

J Biol Chem 2013 Jun 29;288(24):17481-94. Epub 2013 Apr 29.

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, University of Naples Federico II, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M112.439422DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682548PMC
June 2013
11 Reads
4.573 Impact Factor

Hydrocortisone attenuates cyclosporin A-induced nephrotoxicity in rats.

J Cell Biochem 2012 Mar;113(3):997-1004

Department of Structures, Functions and Biological Technologies, School of Veterinary Medicine, University of Naples, Federico II, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.23429DOI Listing
March 2012
4 Reads
3.263 Impact Factor

RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block.

J Clin Endocrinol Metab 2010 Jul 5;95(7):3552-7. Epub 2010 May 5.

Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universitá Federico II, 80131 Naples, Italy.

View Article

Download full-text PDF

Source
https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.
Publisher Site
http://dx.doi.org/10.1210/jc.2009-2315DOI Listing
July 2010
3 Reads
6.209 Impact Factor

Top co-authors

Antonio Giordano
Antonio Giordano

Sbarro Institute for Cancer Research and Molecular Medicine

8
Francesca Pentimalli
Francesca Pentimalli

Università degli Studi di Napoli Federico II

5
Caterina Costa
Caterina Costa

Consiglio Nazionale delle Ricerche

3
Antonella Caporaso
Antonella Caporaso

University of Siena

3
Iris M Forte
Iris M Forte

University of Palermo

2
Carmelina A Iannuzzi
Carmelina A Iannuzzi

Oncology Research Center of Mercogliano (CROM)

2
Paola Indovina
Paola Indovina

University of Siena

2
Luca Esposito
Luca Esposito

Oncology Research Centre of Mercogliano

2
Angela Altieri
Angela Altieri

University of Siena

2
Daniela Barone
Daniela Barone

Università di Napoli

2